Center for Herbal Research on Colorectal Cancer

结直肠癌草药研究中心

基本信息

  • 批准号:
    8299547
  • 负责人:
  • 金额:
    $ 115.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-09-30 至 2015-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Colorectal cancer is the second most prevalent cancer and the second leading cause of cancer related death in the United States. Botanicals could potentially have anti-cancer compounds that may be used alone or as adjuncts to existing chemotherapy to improve efficacy and reduce the drug-induced toxicity. Identifying herbal sources to develop ideal chemoprevention remains an essential step in advancing the treatment of this cancer and will be addressed in the proposed project. The current proposal postulates based on convincing preliminary results and literature reports that two specific herbs from the ginseng family, steamed or unsteamed roots of American ginseng and notoginseng, may have significant anti-cancer activities. The aim of this project is to thoroughly characterize the anti-proliferative actions of test herbs and the underlying mechanisms of action in their direct and adjuvant anti-cancer effects. We hypothesize that American ginseng and notoginseng, particularly after steaming preparation, are effective tumoricidal and chemo-adjuvant compounds against human colorectal cancer. In the proposed project, we will test the tumoricidal effects of these two ginseng herbs on distinct human colorectal cancer cell lines and a mouse xenograft model, and determine the involved mechanisms. We will further test whether the extracts potentiate the tumoricidal effects of colon cancer chemotherapeutic agents, 5-fluorouracil and irinotecan, using the cell lines and mouse model. If synergistic interactions between test herbs and chemotherapeutic drugs exist, then it will enable lowering of the drug dose thus reducing the dose-related toxicity. In addition, whether the newly identified active constituents from steamed herbs increase chemotherapeutic agents' activity will be determined. Finally, pharmacokinetic interaction between the chemotherapeutic drugs and the test herbs, if any, will be characterized. A novelty of this project is the use of "knockout" herbal extracts which will allow a more conclusive association of the effect of the herbal extract to the responsible active constituent(s). Data from the proposed study have a potential to improve treatment regimens and the quality of life for patients suffering from colorectal cancer.
描述(由申请人提供):结直肠癌是美国第二大流行癌症,也是癌症相关死亡的第二大原因。植物药可能具有抗癌化合物,可以单独使用或作为现有化疗的替代品,以提高疗效并降低药物诱导的毒性。确定草药来源以开发理想的化学预防仍然是推进这种癌症治疗的重要步骤,并将在拟议的项目中解决。目前的建议基于令人信服的初步结果和文献报告,假设人参家族的两种特定草药,西洋参和三七的蒸或未蒸的根,可能具有显着的抗癌活性。该项目的目的是彻底描述试验草药的抗增殖作用及其直接和辅助抗癌作用的潜在作用机制。我们推测西洋参和三七,特别是在蒸制后,是有效的杀肿瘤和化学佐剂化合物对人类结直肠癌。在拟议的项目中,我们将测试这两种人参草药对不同的人结直肠癌细胞系和小鼠异种移植模型的杀肿瘤作用,并确定相关机制。我们将使用细胞系和小鼠模型进一步测试提取物是否增强结肠癌化疗剂5-氟尿嘧啶和伊立替康的杀肿瘤作用。如果试验草药和化疗药物之间存在协同相互作用,则可以降低药物剂量,从而降低剂量相关毒性。此外,是否新鉴定的活性成分蒸草药增加化疗药物的活性将被确定。最后,将表征化疗药物和试验草药之间的药代动力学相互作用(如果有的话)。该项目的一个新奇是使用“敲除”草药提取物,这将使草药提取物的作用与负责的活性成分之间的联系更加确定。这项研究的数据有可能改善结直肠癌患者的治疗方案和生活质量。

项目成果

期刊论文数量(83)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
CRISPR clear? Dimeric Cas9-Fok1 nucleases improve genome-editing specificity.
  • DOI:
    10.1016/j.gendis.2014.08.004
  • 发表时间:
    2014-09
  • 期刊:
  • 影响因子:
    6.8
  • 作者:
    Zhang, Hongmei;Yan, Zhengjian;Li, Melissa;Peabody, Michael;He, Tong-Chuan
  • 通讯作者:
    He, Tong-Chuan
Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53.
  • DOI:
    10.1016/j.canlet.2010.11.015
  • 发表时间:
    2011-02-28
  • 期刊:
  • 影响因子:
    9.7
  • 作者:
    Li, Binghui;Zhao, Jiong;Wang, Chong-Zhi;Searle, Jennifer;He, Tong-Chuan;Yuan, Chun-Su;Du, Wei
  • 通讯作者:
    Du, Wei
Phenolic Derivatives from the Root Bark of Oplopanax horridus.
刺五加根皮的酚类衍生物
  • DOI:
    10.1002/hlca.201300439
  • 发表时间:
    2015-02
  • 期刊:
  • 影响因子:
    1.8
  • 作者:
    Huang WH;Zhang QW;Wang CZ;Yuan CS;Li SP
  • 通讯作者:
    Li SP
Bone morphogenetic protein 9 ( BMP 9 ) induces effective bone formation from reversibly immortalized multipotent adipose-derived ( iMAD ) mesenchymal stem cells
  • DOI:
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Shun Lu;Jing Wang;Jixing Ye;Y. Zou;Yunxiao Zhu;Q. Wei;Xin Wang;Shengli Tang;Hao Liu
  • 通讯作者:
    Shun Lu;Jing Wang;Jixing Ye;Y. Zou;Yunxiao Zhu;Q. Wei;Xin Wang;Shengli Tang;Hao Liu
Chemical and pharmacological studies of saponins with a focus on American ginseng.
  • DOI:
    10.5142/jgr.2010.34.3.160
  • 发表时间:
    2010-09-01
  • 期刊:
  • 影响因子:
    6.3
  • 作者:
    Yuan CS;Wang CZ;Wicks SM;Qi LW
  • 通讯作者:
    Qi LW
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHUN-SU YUAN其他文献

CHUN-SU YUAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHUN-SU YUAN', 18)}}的其他基金

Center for Herbal Research on Colorectal Cancer
结直肠癌草药研究中心
  • 批准号:
    7910395
  • 财政年份:
    2008
  • 资助金额:
    $ 115.26万
  • 项目类别:
Center for Herbal Research on Colorectal Cancer
结直肠癌草药研究中心
  • 批准号:
    7691352
  • 财政年份:
    2008
  • 资助金额:
    $ 115.26万
  • 项目类别:
Center for Herbal Research on Colorectal Cancer
结直肠癌草药研究中心
  • 批准号:
    8121645
  • 财政年份:
    2008
  • 资助金额:
    $ 115.26万
  • 项目类别:
SAFETY OF GANODERMA LUCIDUM EXTRACT
灵芝提取物的安全性
  • 批准号:
    7604792
  • 财政年份:
    2007
  • 资助金额:
    $ 115.26万
  • 项目类别:
Herbal Effects on Oxidant Dynamics in Cardiomyocytes
草药对心肌细胞氧化动力学的影响
  • 批准号:
    7415231
  • 财政年份:
    2007
  • 资助金额:
    $ 115.26万
  • 项目类别:
Herbal Effects on Oxidant Dynamics in Cardiomyocytes
草药对心肌细胞氧化动力学的影响
  • 批准号:
    7256174
  • 财政年份:
    2007
  • 资助金额:
    $ 115.26万
  • 项目类别:
SAFETY OF GANODERMA LUCIDUM EXTRACT
灵芝提取物的安全性
  • 批准号:
    7378654
  • 财政年份:
    2006
  • 资助金额:
    $ 115.26万
  • 项目类别:
MULTIPLE-DOSED METHYLNALTREXONE IN VOLUNTEERS
志愿者多次服用甲基纳曲酮
  • 批准号:
    7201008
  • 财政年份:
    2005
  • 资助金额:
    $ 115.26万
  • 项目类别:
EFFECT OF GINSENG ON CISPLATIN-INDUCED EMESIS
人参对顺铂所致呕吐的作用
  • 批准号:
    7033894
  • 财政年份:
    2005
  • 资助金额:
    $ 115.26万
  • 项目类别:
EFFECT OF GINSENG ON CISPLATIN-INDUCED EMESIS
人参对顺铂所致呕吐的作用
  • 批准号:
    6923326
  • 财政年份:
    2005
  • 资助金额:
    $ 115.26万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 115.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 115.26万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 115.26万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 115.26万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 115.26万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 115.26万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 115.26万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 115.26万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 115.26万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 115.26万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了